Elsevier

The Lancet Neurology

Volume 15, Issue 7, June 2016, Pages 650-651
The Lancet Neurology

Comment
Clinical validity of CSF biomarkers for Alzheimer's disease: necessary indeed, but sufficient?

https://doi.org/10.1016/S1474-4422(16)30040-0Get rights and content

References (12)

There are more references available in the full text version of this article.

Cited by (8)

  • Depression in neurodegenerative diseases: Common mechanisms and current treatment options

    2019, Neuroscience and Biobehavioral Reviews
    Citation Excerpt :

    At the neuropathological level, AD is characterized by extracellular deposits of amyloid-β (Aβ) plaques (which result from abnormal breakdown of amyloid precursor protein; APP) and intracellular accumulation of neurofibrillary tangles containing hyperphosphorylated tau protein (Glass et al., 2010; Olsson et al., 2016 Olsson et al., 2016). Of note, cerebrospinal fluid (CSF) levels of tau protein and Aβ show a predictable trend in AD patients, highlighting their use as potential biomarkers to predict onset and progression of this disease (Frisoni and Hansson, 2016; Olsson et al., 2016). Although neurodegeneration in the AD brain is not confined to a discrete neuronal population, cholinergic and γ-aminobutiric acid (GABA)ergic neurons are thought to be particularly vulnerable to this neurodegenerative process (Glass et al., 2010).

  • Serum Protein-Based Profiles for the Diagnostic Model of Alzheimer’s Disease

    2023, American Journal of Alzheimer's Disease and other Dementias
  • CCCDTD5: Clinical role of neuroimaging and liquid biomarkers in patients with cognitive impairment

    2020, Alzheimer's and Dementia: Translational Research and Clinical Interventions
View all citing articles on Scopus
View full text